News
-
-
PRESS RELEASE
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
DBV Technologies screens first participant in THRIVE Phase 2 study of VIASKIN Peanut Patch for infants with peanut allergy. Study aims to achieve ad lib consumption of dietary peanut in infants 6-12 months -
-
-
-
-
-
-
-